The market for myasthenia gravis treatments was valued at USD 1.24 billion in 2021 and is anticipated to grow at a revenue CAGR of 7.5% over the following five years. One of the key reasons influencing the growth of the myasthenia gravis treatment market is the increase in illness prevalence across the globe. For instance, it is predicted that 12.4 people (95% CI 10.6-14.5) worldwide have...